课题基金 / 基金详情

OXALIPLATIN (ELOXATIN) WITH BORTEZOMIB IN PATIENTS WITH ADVANCED MALIGNANCY

OXALIPLATIN (ELOXATIN) WITH BORTEZOMIB IN PATIENTS WITH ADVANCED MALIGNANCY
奥沙利铂(ELOXATIN)联合硼替佐米治疗晚期恶性肿瘤患者
批准号:
7605716
负责人:
HOWARD S HOCHSTER
金额:
$0.99万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-04-01 至 2008-03-31

项目摘要

项目成果

HOWARD S HOCHSTER的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是众多研究子项目之一
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a phase I trial of the combination of oxaliplatin and PS-341 (an inhibitor of ubiquitin-proteasome degradation of p53, IkB, and other cell-cycle regulatory proteins) in the treatment of advanced cancer. The goal is to determine the minimal dose requirements for phase II trials and to determine the toxicities of this combination of agents. Patients will be treated as outpatients and will receive infusions of accelerating doses of PS-341 prior to an infusion of oxaliplatin. Endpoints are the identification of a recommended phase II dose of PS-341 and determination of dose-limiting toxicity. 15-30 patients with advanced cancer, good organ function and lack of prior exposure to certain types of agents (thalidomide, cytoskeleton-active agents) will be enrolled, and participation will involve 26 visits for infusions over 3-6 months. The investigators continue to enroll subjects on this study. No data are available as of yet.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Yale Cancer Center NCTN
  • 批准号:
    8839216
  • 项目类别:
  • 资助金额:
    $55.15万
  • 财政年份:
    2014
  • 负责人:
    HOWARD S HOCHSTER
  • 依托单位:
CLINICAL TRIAL: CETUXIMAB PLUS CAPECITABINE AND OXALIPLATIN FOR METASTATIC COLOR
CLINICAL TRIAL: ALIMTA AND GEMZAR IN ADVANCED PANCREATIC AND BILIARY TRACT CANCE
Clinical Trials Office
国内基金
海外基金
bortezomib抑制寨卡病毒复制的分子机制研究
蛋白酶体抑制剂硼替佐米(Bortezomib)对血管渗漏的改善及机制研究
  • 批准号:
    81772041
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2017
  • 负责人:
    汤耀卿
  • 依托单位:
蛋白酶体抑制剂Bortezomib对肺动脉平滑肌细胞钙离子通路的作用研究
  • 批准号:
    81460011
  • 项目类别:
    地区科学基金项目
  • 资助金额:
    40.0万元
  • 批准年份:
    2014
  • 负责人:
    徐磊
  • 依托单位: